Działania niepożądane leków przeciwnowotworowych stosowanych w onkologii psów i kotów

Piśmiennictwo

Veterinary cooperative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. „Vet Comp Oncol”, 2016, 14 (4), 417-446.Falk E.F., Lam A.T., Barber L.G., Ferrer L.: Clinical characteristics of doxorubicin-associated alopecia in 28 dogs. „Vet Dermatol”, 2017, 28 (2), 207-e48.Mauldin G.E., Fox P.R., Patnaik A.K., Bond B.R., Mooney S.C., Matus R.E.: Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. „J Vet Intern Med”, 1992, 6 (2), 82-8.Wang S.L., Lee J.J., Liao A.T.: Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. „Can Vet J”, 2016, 57 (3), 271-6.Back A.R., Schleis S.E., Smrkovski O.A., Lee J., Smith A.N., Phillips J.C.: Mechlorethamine, vincristine,melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. „Vet Comp Oncol”, 2015, 13 (4), 398-408.Brown P.M., Tzannes S., Nguyen S., White J., Langova V.: LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. „Vet Comp Oncol”, 2018, 16 (1), 108-113.Frimberger A.E., Chan C.M., Moore A.S.: Canine osteosarcoma treated by post- amputation sequential accelerated doxorubicin and carboplatin chemotherapy: 38 Cases. „J Am Anim Hosp Assoc”, 2016, 52 (3), 149-56.Harper A., Blackwood L.: Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer-bearing dogs: a retrospective study. „J Small Anim Pract”, 2017, 58 (4), 227-230.Marrington A.M., Killick D.R., Grant I.A., Blackwood L.: Toxicity associated with epirubicin treatments in a large case series of dogs. „Vet Comp Oncol”, 2012, 10 (2), 113-23.Vail D.M.: Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. „Top Companion Anim Med”, 2009, 24 (3), 122-9.Bailey D.B., Rassnick K.M., Erb H.N. et al.: Effect of glomerular filtration rate on clearance and myelotoxicity...